US$ 22.52
igf-1 lr3 100mcg vial IGF-1 LR3 PEPTIDE 1MG/10MG VIAL
Description
Moncada et al

Busi MV, Barchiesi J, Martn M, Gomez-Casati DF

D., Flanders, T

Extended low-dose designs suit aging or longevity research where the objective is sustained metabolic improvement over months rather than weeks

All other cells were classified as S phase

(PubMed) Choi HK, Gao X, Curhan G
